Floatz logo

gsk1120212

Tumor Skin

TriHealth Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Tumor Skin cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Rapamycin
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
TACROLIMUS
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Nivolumab
UNICANCER
Phase 2B
TRASTUZUMAB
Cancer Research UK
Phase 2/3B

View all 24 →

Same molecule, other indications

gsk1120212 is also rated in:

anaplastic pleomorphic xanthoastrocytomaDormant
BB
Indicative ·
69 / 100
View asset →
Glioma, High GradeDormant
BB
Indicative ·
69 / 100
View asset →
anaplastic oligodendrogliomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →